Norwalk Leslie V — SEC Form 4 filings
SEC reporting owner CIK 1533568. 25 Form 4 filings on record with FilingPulse; latest filed 2026-07-30.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2024-01-30 to 2026-07-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 10 filings — 39,196 shares, $4,394,294 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: sale of 8,000 shares @ $135.67 ($1,085,388) in NEUROCRINE BIOSCIENCES INC, filed 2024-02-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Director | 10 | — | 7 legs · 21,606 sh · $3,216,120 | 20 |
| GLOBUS MEDICAL INC (GMED) | Director | 7 | — | 4 legs · 17,590 sh · $1,178,174 | 3 |
| ARVINAS, INC. (ARVN) | Director | 3 | — | — | 6 |
| CVS HEALTH Corp (CVS) | Director | 4 | — | — | 4 |
| ModivCare Inc (MODV) | Director | 1 | — | — | 1 |
Form 4 filings — Norwalk Leslie V
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-30 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,250 @ $182.01 · Option exercise (M): 842 @ $139.43 · Option exercise (M): 842 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | ARVINAS, INC. (ARVN) | Grant/award (A): 15,527 @ $0 · Grant/award (A): 22,714 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,250 @ $168.06 | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 1,284 (derivative) @ $0 · Grant/award (A): 2,624 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,659 @ $0 · Option exercise (M): 1,659 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | CVS HEALTH Corp (CVS) | Grant/award (A): 1,447 @ $97.15 | EDGAR |
| 2026-05-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 3,810 @ $155.01 | EDGAR |
| 2026-01-23 | 4 | GLOBUS MEDICAL INC (GMED) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | GLOBUS MEDICAL INC (GMED) | Sale (S): 2,000 @ $101.10 | EDGAR |
| 2025-12-17 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 8,276 @ $92.35 · Option exercise (M): 1,724 @ $84.95 · Sale (S): 5,000 @ $152.23 · Sale (S): 1,190 @ $155.09 · Option exercise (M): 8,276 (derivative) @ $0 · Option exercise (M): 1,724 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | GLOBUS MEDICAL INC (GMED) | Sale (S): 4,000 @ $88.85 | EDGAR |
| 2025-11-21 | 4 | CVS HEALTH Corp (CVS) | Grant/award (A): 1,652 @ $76.04 | EDGAR |
| 2025-06-27 | 4 | ARVINAS, INC. (ARVN) | Grant/award (A): 16,025 @ $0 · Grant/award (A): 23,105 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,435 @ $0 · Grant/award (A): 1,659 (derivative) @ $0 · Grant/award (A): 3,305 (derivative) @ $0 · Option exercise (M): 1,435 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | CVS HEALTH Corp (CVS) | Grant/award (A): 2,077 @ $60.47 | EDGAR |
| 2025-03-28 | 4 | GLOBUS MEDICAL INC (GMED) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | CVS HEALTH Corp (CVS) | Grant/award (A): 2,200 @ $57.10 | EDGAR |
| 2024-07-15 | 4 | GLOBUS MEDICAL INC (GMED) | Sale (S): 1,000 @ $70 | EDGAR |
| 2024-05-31 | 4 | ARVINAS, INC. (ARVN) | Grant/award (A): 5,899 @ $0 · Grant/award (A): 9,070 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 1,435 (derivative) @ $0 · Grant/award (A): 2,982 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,100 @ $0 · Sale (S): 1,106 @ $141.82 · Option exercise (M): 2,100 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | GLOBUS MEDICAL INC (GMED) | Sale (S): 10,590 @ $51.99 | EDGAR |
| 2024-02-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 8,000 @ $84.95 · Sale (S): 8,000 @ $135.67 · Option exercise (M): 8,000 (derivative) @ $84.95 | EDGAR |
| 2024-02-16 | 4 | ModivCare Inc (MODV) | Grant/award (A): 2,658 @ $0 | EDGAR |
| 2024-01-30 | 4 | GLOBUS MEDICAL INC (GMED) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1533568 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →